Interphase fluorescence in situ hybridization analysis of CD19‐selected cells: Utility in detecting disease in post‐therapy samples of B‐cell neoplasms

Autor: Caitlin E. Walsh, Vundavalli V. Murty, Bachir Alobeid, Govind Bhagat, Andrew M. Parrott, Alecia Christiano
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Cancer Research
Pathology
CD19‐selection
Somatic evolution in cancer
B‐cell
cytogenetics
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Neoplasm
Child
In Situ Hybridization
Fluorescence
Original Research
Aged
80 and over
medicine.diagnostic_test
leukemia
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Survival Rate
Oncology
Child
Preschool
030220 oncology & carcinogenesis
Female
Adult
measurable residual disease
medicine.medical_specialty
Lymphoma
B-Cell
minimal disease
Adolescent
Antigens
CD19
lymphoma
Context (language use)
Biology
lcsh:RC254-282
Flow cytometry
Young Adult
03 medical and health sciences
FISH
medicine
Humans
Radiology
Nuclear Medicine and imaging
Interphase
Aged
Retrospective Studies
Chromosome Aberrations
flow cytometry
Cytogenetics
Clinical Cancer Research
medicine.disease
Lymphoma
post‐therapy
karyotype
030104 developmental biology
Cytometry
neoplasm
Follow-Up Studies
Fluorescence in situ hybridization
Zdroj: Cancer Medicine, Vol 10, Iss 8, Pp 2680-2689 (2021)
Cancer Medicine
ISSN: 2045-7634
Popis: Context The detection of low‐level persistent or relapsed B‐cell neoplasms, particularly post‐therapy, can be challenging, often requiring multiple testing modalities. Objective Here we investigate the utility of CD19‐based selection of neoplastic B‐cells (CD19S) as an enrichment strategy to improve the detection rate of cytogenetic abnormalities in post‐therapy samples of B‐cell neoplasms, especially those with low‐level disease. Design In a cohort largely comprised of post‐therapy B‐ALL and CLL samples, we performed fluorescence in situ hybridization (FISH) analysis on CD19‐selected cells (CD19S FISH) in 128 specimens from 88 patients, and on non‐selected cells (NS FISH) in a subset of cases. The FISH findings were compared with the concurrent flow cytometry (FC) results in all samples and molecular analysis in a subset. Results CD19S FISH was able to detect cytogenetic aberrations in 86.0% of post‐therapy samples with evidence of disease as determined by routine or MRD FC, compared to 59.1% of samples by NS FISH. CD19S FISH detected significantly higher percentages of positive cells compared to NS FISH (p
A systematic comparison of CD19‐selected (CD19S) FISH versus non‐selected FISH analysis establishes superiority (qualitative and quantitative) of the former modality in detecting post‐therapy persistence or relapse of B‐cell neoplasms. CD19S FISH can complement flow cytometric evaluation for the detection of low‐level involvement in B‐cell neoplasms and particularly in the detection of post‐therapy recurrent/emerging small subclones. Flow cytometry detection of
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje